ClinicalTrials.gg
Enrolling by invitationNCT06959784Updated May 7, 2025

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

A Phase 4 interventional study of semaglutide and Metformin in Diabetes Mellitus, Cardiovascular Diseases and Cerebrovascular Disease, sponsored by China-Japan Friendship Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by China-Japan Friendship Hospital · Phase 4, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.

Planned enrollment
35th of 82
142 · median 100
Started
2024
with 4 others
Phase 4
10 of 82
6 open now
Primary completion
2026-12
later than 4 of 13 live
Registered
78th of 82
by date
Lead sponsor
1 of 82
China-Japan Friendship Hospital

Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 35th largest by planned enrollment, is one of 5 that started in 2024, is one of 10 in phase 4, reaches primary completion later than 4 of the 13 other live ones, and was the 78th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing semaglutide in Diabetes Mellitus, or all of them as a file.
02

Study summary

This study used the diabetes prevention and follow-up research queue in Daqing and the public database of UKbiobank to evaluate the risk factors of cardiovascular and cerebrovascular events in diabetes patients, and built the first risk prediction model of cardiovascular and cerebrovascular events in diabetes patients based on the Chinese population follow-up queue and externally verified, so as to identify high-risk groups and guide the early prevention of cardiovascular and cerebrovascular diseases in diabetes patients. To evaluate the effect of incretin drugs on reducing the risk of cardiovascular and cerebrovascular events, and the impact on the remission rate of diabetes in people with initial diabetes, a randomized, multicenter, controlled clinical study was conducted. The long-term follow-up of 2 years was conducted to evaluate whether the cardiovascular and cerebrovascular risks of those who stopped drug treatment after remission of diabetes compared with those who continued drug treatment were reduced, as well as the long-term impact of incretin on cardiovascular and cerebrovascular risks and the role of long-term mitigation of diabetes.

03

Conditions studied

  • Diabetes Mellitus
  • Cardiovascular Diseases
  • Cerebrovascular Disease
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed diabetes, with no previous use of hypoglycemic medications or having discontinued such medications for more than 3 months.
  • Blood glucose elevation detected within one year (fasting blood glucose exceeding 7 mmol/L, postprandial blood glucose or random blood glucose exceeding 11.1 mmol/L).
  • Age between 30 and 70 years (inclusive of boundary values).
  • between 7% and 10% (inclusive of boundary values).
  • between 24 and 32.5 kg/m² (inclusive of boundary values).

Exclusion criteria

Exclusion Criteria:

  • History of coronary heart disease or cerebral infarction.
  • Severe liver or kidney disease: (ALT) or aspartate aminotransferase (AST) > 3 times the (ULN); less than 30 ml/min/1.73 m².
  • History of malignant tumors.
  • Use of systemic (excluding local applications or inhalants) for one week or more within the three months prior to screening.
  • Positive urine pregnancy test in women of childbearing age.
  • History of pancreatitis, or amylase and/or lipase > 3 times the ULN.
  • Personal history or family history of medullary thyroid carcinoma (MTC) in first-degree relatives, or genetic predisposition to MTC (such as multiple endocrine neoplasia syndrome).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Placebo comparator
    Metformin control group

    The metformin control group received metformin (gradually increased to 1 g bid) for 24 weeks (6 months)

    Drug: Metformin

  • Experimental
    semaglutide group

    The Semaglutide intervention group received semaglutide (starting at 0.25mg qw and increasing to 0.5mg qw after four weeks) for 24 weeks (6 months).

    Drug: semaglutide

Interventions

  • The semaglutide intervention group received semaglutide (0.25 mg qw initially, increased to 0.5 mg qw after four weeks) for 24 weeks (6 months).

  • DrugMetformin

    The metformin control group was treated with metformin (gradually increasing to 1g bid) for 24 weeks (6 months)

06

What researchers measure

Primary outcomes

  1. Cardiovascular and cerebrovascular event risk score

    The cardiovascular and cerebrovascular event score (0-100%)is based on the cardiovascular and cerebrovascular event risk prediction model for diabetic patients established in Objective 1. In this prediction model, age, gender, smoking status, body mass index, waist circumference, glycated hemoglobin, blood sugar, blood pressure, and blood lipids correspond to certain scores. Higher scores indicate a higher risk of cardiovascular and cerebrovascular events and a worse outcome.

    Time frame: One-year follow-up

  2. Major Adverse Cardiovascular Events

    The Mace event includes cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

    Time frame: Baseline and every 12 weeks until 96 weeks

  3. Cerebrovascular disease events

    Cerebrovascular diseases include ischemic stroke, hemorrhagic stroke, transient ischemic attack, cerebral vascular malformation, etc.

    Time frame: Baseline and every 12 weeks until 96 weeks

Secondary outcomes

  1. The remission rate of diabetes

    Time frame: at 9 months, 1 year and 2 years of follow-up

  2. Glycated hemoglobin

    Reduced levels of glycated hemoglobin

    Time frame: Baseline and every 12 weeks until 96 weeks

  3. Fasting and postprandial blood glucose levels

    Time frame: at 2 year and 8 year of follow-up

  4. pancreatic islet function

    The study evaluated pancreatic islet cell function by testing fasting insulin, insulin one hour after a steamed bread meal, and insulin two hours after a steamed bread meal.

    Time frame: Baseline, 48 weeks and 96 weeks

  5. Heart rate

    The heart rate of the subjects were measured by electrocardiogram when they were at rest.

    Time frame: Baseline, 48 weeks and 96 weeks

  6. Carotid artery peak systolic velocity

    Evaluate the systolic peak blood flow velocity through carotid artery ultrasound.

    Time frame: Baseline, 48 weeks and 96 weeks

  7. Routine urine examination

    Evaluate the levels of red blood cells, white blood cells, urine glucose, urine ketones, and urine protein in urine through urine routine testing.

    Time frame: Baseline, 48 weeks and 96 weeks

  8. Urine microalbumin

    Urine microalbuminuria for early assessment of renal damage.

    Time frame: Baseline, 48 weeks and 96 weeks

  9. Heart rhythm

    The heart rhythm of the subjects were measured by electrocardiogram when they were at rest.

    Time frame: Baseline, 48 weeks and 96 weeks

  10. Carotid artery peak diastolic velocity

    Evaluate the diastolic peak blood flow velocity through carotid artery ultrasound.

    Time frame: Baseline, 48 weeks and 96 weeks

  11. Carotid resistance index

    Evaluate resistance index through carotid artery ultrasound. Carotid resistance index = (peak systolic velocity - end diastolic velocity) / peak systolic velocity

    Time frame: Baseline, 48 weeks and 96 weeks

  12. common carotid artery diameter

    Evaluate the common carotid artery diameter through carotid artery ultrasound.

    Time frame: Baseline, 48 weeks and 96 weeks

  13. Carotid artery wall thickness

    Evaluate the wall thickness through carotid artery ultrasound.

    Time frame: Baseline, 48 weeks and 96 weeks

  14. Carotid Intima-media Thickness

    Evaluate the intimal thickness through carotid artery ultrasound.

    Time frame: Baseline, 48 weeks and 96 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 149 non-industry phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 35 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 7, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06959784
Responsible party
Bo Zhang (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
May 7, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion